DSC Investment
VC Fund
Seoul, South Korea
DSC Investment is a VC fund in Seoul focused on Artificial Intelligence and Software. DSC Investments invests in early stage and growth companies in the field of corporate identify and focus, IT, software, biotechnology, machinery, and future high-growth areas such as environment and resources.
- Total investments:
- 229
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries DSC Investment invests in
Stages DSC Investment invests in
Countries DSC Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $594k–$9.1M
- Series A
- $1.6M–$17M
- Series B
- $4.5M–$54M
Investment Focus
Industry
- Artificial Intelligence 26 (11%)
- Software 21 (9%)
- Health Care 20 (9%)
- Information Technology 20 (9%)
- Biotechnology 18 (8%)
Stage
- Series A 77 (34%)
- Series B 51 (22%)
- Seed 41 (18%)
- Series C 16 (7%)
- Funding Round 6 (3%)
Country
- South Korea 128 (56%)
- United States 16 (7%)
- Israel 2 (1%)
- Thailand 1 (0%)
- Russian Federation 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Han Tae Hoon
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Junam Kim
Director
|
Director | Total investments: 4 | Find email | |
|
Kyungho Lee
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
|
Lee Yong-hyun
Head of the DSC Investment team
|
Head of the DSC Investment team | Total investments: 3 | Find email | |
|
Yohan Kim
Senior Managing Director
|
Senior Managing Director | Total investments: 4 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MID
|
MID specializes in the development, testing, and production of space-related components. | $10.8M / Series A / Jul 29, 2026 | |
CarbonSix
|
CarbonSix develops AI-powered robotics technologies for manufacturing automation, with a focus on tasks that involve high product variation and changing production conditions. Its platform uses imitation learning to enable industrial robots to learn from human demonstrations and perform complex manipulation tasks that are difficult to automateusing conventional programming methods. The company combines robotics hardware and AI software to improve robot adaptability while meeting industrial quality and reliability requirements. Its solutions are designed for manufacturing environments where flexible automation is needed for assembly and other variable production processes. | $40M / Series A / Jul 01, 2026 | |
Inocras
|
Inocras Inc. specializes in whole genome sequencing and analytics, focusing on providing insights for personalized care in cancer and rare diseases. Utilizing artificial intelligence, Inocras aims to revolutionize healthcare by enabling precision medicine. The company offers services to patients, healthcare providers, researchers, and partners,seeking to unlock new possibilities in precision health. With a commitment to innovation, Inocras has introduced products like CancerVision and RareVision, designed to enhance diagnosis and treatment strategies through comprehensive genomic analysis. | $20K / Series B / Jul 01, 2026 | |
Clobe AI
|
Clobe AI is a SaaS-based financial management platform designed for businesses to monitor and manage cash flow and financial operations. The company provides services such as real-time aggregation of financial data from bank accounts, corporate cards, and tax invoices, along with automated accounting and tax handling. The platform also supportscash flow tracking, profit and loss analysis, and automated settlement workflows, including transaction mapping and invoice processing, enabling centralized financial reporting and operational control. | $9.1M / Seed / Mar 11, 2026 | |
Clobe ai
|
Clobe ai is an AI‑powered financial platform that simplifies money management for individuals and small‑to‑medium businesses. | $9.1M / Seed / Mar 11, 2026 | |
Ark
|
Ark is an AI-based early screening company focused on identifying and preventing complications associated with chronic diseases, developing and supplying advanced medical AI solutions that enable early detection, risk assessment, and proactive disease management to support healthcare providers in delivering more precise and timely care. | $13.5M / Series A / Mar 05, 2026 | |
Orum Therapeutics
|
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M / Post-IPO Equity / Dec 18, 2025 | |
arcreal
|
arcreal is involved in developing intraoral scanners, medical software, and dental platforms with the goal of digital transformation in the dental industry. They produce different technologies, such as an intraoral scanner, CAD software, and a digital platform. | $5.4M / Seed / Dec 16, 2025 | |
Pharos iBio Co.
|
Pharos iBio Co. specializing in drug development that develops treatments for intractable diseases. | $12.9M / Post-IPO Debt / Dec 04, 2025 | |
PineTree Therapeutics
|
PineTree Therapeutics engages in the development of disruptive therapies in Oncology and Immuno-oncology. | $47M / Series B / Oct 28, 2025 | |
| See all 229 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does DSC Investment invest in?
DSC Investment invests primarily in Artificial Intelligence, Software and Health Care startups, most often at Series A and Series B stage. Most of the 229 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is DSC Investment's check size?
DSC Investment typically joins rounds of $594k–$9.1M at Seed, $1.6M–$17M at Series A and $4.5M–$54M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DSC Investment participates in.
How do I contact DSC Investment?
Public channels for DSC Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DSC Investment?
The team at DSC Investment includes Han Tae Hoon (Managing Director), Junam Kim (Director) and Kyungho Lee (Managing Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
